Tetrahydrofuran
Search Within Results
1
–
2
of
2
results
1
Medchemexpress LLC 2-((5-((4-fluorophenyl)carbamoyl)pyrimidinyl)sulfanylmethyl)-4-(trifluoromethoxy)phenyl boronic acid | 1648843-04-2 | 98.7% | 25 MG
SX-682 (CAS 1648843-04-2) is an orally bioavailable small-molecule allosteric inhibitor of CXCR1 and CXCR2 investigated for oncology research. It blocks recruitment of immunosuppressive myeloid-derived suppressor cells to the tumor microenvironment and can enhance the activity of checkpoint inhibitors.
- Oral bioavailability and potent CXCR1/2 antagonism
- Useful for preclinical and clinical oncology research
- Blocks myeloid-derived suppressor cell recruitment to tumors
- Well-characterized chemical identity: CAS 1648843-04-2, C19H14BF4N3O4S
- Analytical purity typically >98% and supplied as a 25 MG vial
2
![Medchemexpress LLC 2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl boronic acid | 1648843-04-2 | 99.7% | 10 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000234135.png-250.jpg)
Medchemexpress LLC 2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl boronic acid | 1648843-04-2 | 99.7% | 10 MG
SX-682 is an orally bioavailable small-molecule allosteric inhibitor of chemokine receptors CXCR1 and CXCR2 under clinical investigation for oncology indications; it blocks recruitment of myeloid-derived suppressor cells and can enhance T-cell activity.
- Orally bioavailable small-molecule CXCR1/2 inhibitor
- Blocks recruitment of myeloid-derived suppressor cells (MDSCs)
- Enhances T-cell activation and antitumor immune responses
- Demonstrated activity in preclinical tumor models and clinical trials
- Supplied with high purity (typical >99%) and available in small-mass packaging for research